vs

Side-by-side financial comparison of MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) and STAAR SURGICAL CO (STAA). Click either name above to swap in a different company.

MARAVAI LIFESCIENCES HOLDINGS, INC. is the larger business by last-quarter revenue ($49.9M vs $49.0M, roughly 1.0× STAAR SURGICAL CO). STAAR SURGICAL CO runs the higher net margin — -69.9% vs -71.6%, a 1.6% gap on every dollar of revenue. On growth, MARAVAI LIFESCIENCES HOLDINGS, INC. posted the faster year-over-year revenue change (-11.8% vs -35.8%). STAAR SURGICAL CO produced more free cash flow last quarter ($-5.1M vs $-24.9M). Over the past eight quarters, MARAVAI LIFESCIENCES HOLDINGS, INC.'s revenue compounded faster (-11.9% CAGR vs -18.4%).

Maravai LifeSciences Holdings is a global life sciences firm developing critical reagents, diagnostic products, and tech solutions to support biopharma research, drug development, clinical diagnostics, and cell/gene therapy manufacturing. It serves biotech, pharma, research bodies and labs worldwide across three core segments.

STAAR Surgical Co is a global ophthalmic medical device firm. It designs, makes and sells implantable collamer lenses (ICLs) for minimally invasive vision correction, plus supporting surgical products for ophthalmologists across North America, Europe, Asia Pacific and other key regional markets.

MRVI vs STAA — Head-to-Head

Bigger by revenue
MRVI
MRVI
1.0× larger
MRVI
$49.9M
$49.0M
STAA
Growing faster (revenue YoY)
MRVI
MRVI
+24.0% gap
MRVI
-11.8%
-35.8%
STAA
Higher net margin
STAA
STAA
1.6% more per $
STAA
-69.9%
-71.6%
MRVI
More free cash flow
STAA
STAA
$19.8M more FCF
STAA
$-5.1M
$-24.9M
MRVI
Faster 2-yr revenue CAGR
MRVI
MRVI
Annualised
MRVI
-11.9%
-18.4%
STAA

Income Statement — Q4 FY2025 vs Q4 FY2024

Metric
MRVI
MRVI
STAA
STAA
Revenue
$49.9M
$49.0M
Net Profit
$-35.7M
$-34.2M
Gross Margin
25.8%
64.7%
Operating Margin
-117.9%
-57.0%
Net Margin
-71.6%
-69.9%
Revenue YoY
-11.8%
-35.8%
Net Profit YoY
-37.7%
-541.3%
EPS (diluted)
$-0.24
$-0.69

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MRVI
MRVI
STAA
STAA
Q4 25
$49.9M
Q3 25
$41.6M
Q2 25
$47.4M
Q1 25
$46.9M
Q4 24
$56.6M
$49.0M
Q3 24
$69.0M
$88.6M
Q2 24
$69.4M
$99.0M
Q1 24
$64.2M
$77.4M
Net Profit
MRVI
MRVI
STAA
STAA
Q4 25
$-35.7M
Q3 25
$-25.6M
Q2 25
$-39.6M
Q1 25
$-29.9M
Q4 24
$-25.9M
$-34.2M
Q3 24
$-97.1M
$10.0M
Q2 24
$-9.8M
$7.4M
Q1 24
$-12.1M
$-3.3M
Gross Margin
MRVI
MRVI
STAA
STAA
Q4 25
25.8%
Q3 25
13.6%
Q2 25
16.4%
Q1 25
16.5%
Q4 24
34.3%
64.7%
Q3 24
46.7%
77.3%
Q2 24
44.4%
79.2%
Q1 24
40.3%
78.9%
Operating Margin
MRVI
MRVI
STAA
STAA
Q4 25
-117.9%
Q3 25
-98.6%
Q2 25
-139.8%
Q1 25
-104.9%
Q4 24
-66.7%
-57.0%
Q3 24
-239.9%
6.4%
Q2 24
-19.4%
12.0%
Q1 24
-29.4%
-2.9%
Net Margin
MRVI
MRVI
STAA
STAA
Q4 25
-71.6%
Q3 25
-61.4%
Q2 25
-83.5%
Q1 25
-63.9%
Q4 24
-45.8%
-69.9%
Q3 24
-140.6%
11.3%
Q2 24
-14.1%
7.5%
Q1 24
-18.8%
-4.3%
EPS (diluted)
MRVI
MRVI
STAA
STAA
Q4 25
$-0.24
Q3 25
$-0.18
Q2 25
$-0.27
Q1 25
$-0.21
Q4 24
$-0.21
$-0.69
Q3 24
$-0.68
$0.20
Q2 24
$-0.07
$0.15
Q1 24
$-0.09
$-0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MRVI
MRVI
STAA
STAA
Cash + ST InvestmentsLiquidity on hand
$216.9M
$230.5M
Total DebtLower is stronger
$291.8M
Stockholders' EquityBook value
$212.4M
$397.3M
Total Assets
$770.6M
$509.5M
Debt / EquityLower = less leverage
1.37×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MRVI
MRVI
STAA
STAA
Q4 25
$216.9M
Q3 25
$243.6M
Q2 25
$269.9M
Q1 25
$285.1M
Q4 24
$322.4M
$230.5M
Q3 24
$578.2M
$236.0M
Q2 24
$573.2M
$235.2M
Q1 24
$561.7M
$245.1M
Total Debt
MRVI
MRVI
STAA
STAA
Q4 25
$291.8M
Q3 25
$292.8M
Q2 25
$293.9M
Q1 25
$294.9M
Q4 24
$295.9M
Q3 24
$521.7M
Q2 24
$522.5M
Q1 24
$523.3M
Stockholders' Equity
MRVI
MRVI
STAA
STAA
Q4 25
$212.4M
Q3 25
$245.4M
Q2 25
$265.9M
Q1 25
$300.6M
Q4 24
$325.3M
$397.3M
Q3 24
$344.9M
$428.1M
Q2 24
$434.7M
$409.1M
Q1 24
$410.7M
$392.8M
Total Assets
MRVI
MRVI
STAA
STAA
Q4 25
$770.6M
Q3 25
$849.2M
Q2 25
$897.0M
Q1 25
$959.8M
Q4 24
$1.0B
$509.5M
Q3 24
$1.3B
$537.6M
Q2 24
$1.4B
$512.7M
Q1 24
$1.4B
$492.5M
Debt / Equity
MRVI
MRVI
STAA
STAA
Q4 25
1.37×
Q3 25
1.19×
Q2 25
1.11×
Q1 25
0.98×
Q4 24
0.91×
Q3 24
1.51×
Q2 24
1.20×
Q1 24
1.27×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MRVI
MRVI
STAA
STAA
Operating Cash FlowLast quarter
$-22.8M
$642.0K
Free Cash FlowOCF − Capex
$-24.9M
$-5.1M
FCF MarginFCF / Revenue
-49.9%
-10.4%
Capex IntensityCapex / Revenue
4.2%
11.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-70.7M
$-7.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MRVI
MRVI
STAA
STAA
Q4 25
$-22.8M
Q3 25
$-15.2M
Q2 25
$-10.3M
Q1 25
$-9.4M
Q4 24
$-14.6M
$642.0K
Q3 24
$13.1M
$3.8M
Q2 24
$17.4M
$-10.4M
Q1 24
$-8.5M
$21.7M
Free Cash Flow
MRVI
MRVI
STAA
STAA
Q4 25
$-24.9M
Q3 25
$-18.1M
Q2 25
$-13.1M
Q1 25
$-14.6M
Q4 24
$-20.5M
$-5.1M
Q3 24
$4.5M
$-2.4M
Q2 24
$7.9M
$-16.6M
Q1 24
$-14.1M
$16.5M
FCF Margin
MRVI
MRVI
STAA
STAA
Q4 25
-49.9%
Q3 25
-43.4%
Q2 25
-27.7%
Q1 25
-31.2%
Q4 24
-36.2%
-10.4%
Q3 24
6.6%
-2.7%
Q2 24
11.4%
-16.8%
Q1 24
-22.0%
21.3%
Capex Intensity
MRVI
MRVI
STAA
STAA
Q4 25
4.2%
Q3 25
7.0%
Q2 25
6.1%
Q1 25
11.2%
Q4 24
10.3%
11.7%
Q3 24
12.4%
7.0%
Q2 24
13.8%
6.3%
Q1 24
8.8%
6.7%
Cash Conversion
MRVI
MRVI
STAA
STAA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.38×
Q2 24
-1.41×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MRVI
MRVI

Cygnus Segment$27.2M54%
Other$18.4M37%
Shipping And Handling$4.3M9%

STAA
STAA

Segment breakdown not available.

Related Comparisons